Palopegteriparatide in Adults With Hypoparathyroidism: 3.5-Year Results From the Phase 3 PaTHway Trial

Clicks: 14
ID: 337460
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #406 of 449 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 449 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
CONTEXT: Palopegteriparatide offers a parathyroid hormone (PTH) replacement option that addresses the multiorgan consequences of hypoparathyroidism. OBJECTIVE: Evaluate the long-term safety and efficacy of palopegteriparatide in adults with hypoparathyroidism. DESIGN: Phase 3 trial with a 26-week, randomized, double-blind, placebo-controlled period followed by a 156-week, open-label extension (OLE). SETTING: Twenty-one North American and European sites. PARTICIPANTS: Eighty-two adults with hypoparathyroidism were randomized and received study drug and 73 completed Week 182. INTERVENTION(S): Palopegteriparatide initiated at 18 µg/day (or corresponding volume of placebo) with progressive titration for 26 weeks, followed by a 156-week OLE period during which all received titrated palopegteriparatide treatment. MAIN OUTCOME MEASURE(S): Efficacy assessments included independence from conventional therapy (≤600 mg/day of elemental calcium and no active vitamin D) and maintenance of normocalcemia (8.3 to 10.6 mg/dL [2.07 to 2.64 mmol/L]). Renal endpoints, skeletal measures, and patient-reported outcomes were monitored at prespecified intervals. Safety assessments included adverse events (AEs) and laboratory monitoring. RESULTS: At Week 182, 96% of participants (70/73) were independent from therapeutic doses of calcium, 100% (73/73) were independent from active vitamin D, and 89% (65/73) were normocalcemic. Mean bone turnover marker values increased from and stabilized above baseline values. Mean bone mineral density (BMD) Z-scores trended towards age- and sex-matched norms, remaining above zero. Early normalization of mean 24-hour urine calcium excretion, gains in mean estimated glomerular filtration rate (eGFR), and improvement in patient-reported outcomes were preserved through Week 182. Most AEs were mild-to-moderate. CONCLUSION: Palopegteriparatide demonstrated durable safety and efficacy as a PTH replacement therapy in adults with hypoparathyroidism over 3.5 years.
Reference Key
openalex_W7223939459 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Aliya A Khan, Bart Lyman Clarke, Mishaela Ruth Rubin, Peter E. H. Schwarz, Dolores Shoback, Claudia Gagnon, Andrea Palermo, Lisa G Abbott, Lynn Kohlmeier, Elena A. Tsourdi, Filomena Cetani, Rajesh K. Jain, Mark Warren, Carol Zhao, Zhao Lu, Alden Raymond Smith, Bryant Lai, Michael S. Ominsky, Jenny Ukena, Christopher T. Sibley, Aimee D Shu, Lars Rejnmark
Are you one of these authors? Claim your profile
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag440
URL
https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgag440/72531048/dgag440.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.